EANS-News: Intercell AG
Intercell starts the second part of a Phase I clinical
trial with vaccine candidate to prevent Clostridium difficile infections
01.03.2012 – 08:08
-------------------------------------------------------------------------------- Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. -------------------------------------------------------------------------------- Research & Development Wien (euro adhoc) - - » Trial in vaccine target group of elderly subjects (elderly >65 years) initiated » First data from Phase I clinical trial showed good safety and immunogenicity of the vaccine candidate against Clostridium difficile, the major cause of nosocomial diarrhea, in healthy young adults » Study aims to obtain safety and immunogenicity data in elderly subjects with results expected in Q2 2013 Vienna (Austria), March 1, 2012 - Intercell AG (VSE: ICLL) today announced the start of the second half of a Phase I clinical trial with the company's vaccine candidate IC84 to prevent disease caused by the bacterium Clostridium difficile (C. difficile). First data from the Phase I study (Phase Ia) in a population of healthy adults aged 18-65 years showed good safety and immunogenicity of the vaccine candidate, and indicated functionality of induced antibodies in this study population. This supported the decision to carry forward the vaccine candidate for safety and dose-confirmation in the elderly. The second part of the Phase I study (Phase Ib) will enroll 80 healthy elderly subjects above 65 years of age, as this age group represents the main target population for a C. difficile vaccine. Two vaccine concentrations will be tested with and without alum to confirm the vaccine dose and necessity of the adjuvant in the elderly. Compared to the Phase Ia part of the study in healthy young adults, the vaccination schedule has been modified to potentially optimize the immune response in elderly subjects who might respond differently to the vaccination due to their immunosenescence. Intercell's vaccine candidate is a recombinant fusion protein consisting of two truncated toxins A and B from C. difficile. The toxins are known to be disease-causing and anti-toxin immunity can be protective. The pathogen C. difficile is one of the main causes of nosocomial diarrhea. Further inquiry note: Intercell AG Nina Waibel Corporate Communications Tel. +43 1 20620-1222 communications@intercell.com end of announcement euro adhoc -------------------------------------------------------------------------------- company: Intercell AG Campus Vienna Biocenter 3 A-1030 Wien phone: +43 1 20620-0 FAX: +43 1 20620-800 mail: investors@intercell.com WWW: www.intercell.com sector: Biotechnology ISIN: AT0000612601 indexes: ATX Prime stockmarkets: official market: Wien language: English